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A B S T R A C T
The purpose of this study was to develop a PLGA microspheres-based donepezil (DP) for-
mulation which was expected to sustain release of DP for one week with high encapsulation
efficiency (EE). DP derived from donepezil hydrochloride was encapsulated in PLGA
microspheres by the O/W emulsion-solvent evaporation method. The optimized formula-
tion which avoided the crushing of microspheres during the preparation process was
characterized in terms of particle size, morphology, drug loading and EE, physical state of
DP in the matrix and in vitro and in vivo release behavior. DP microspheres were prepared
successfully with average diameter of 30 µm, drug loading of 15.92 ± 0.31% and EE up to
78.79 ± 2.56%. Scanning electron microscope image showed it has integrated spherical shape
with no drug crystal and porous on its surface. Differential scanning calorimetry and X-ray
diffraction results suggested DP was in amorphous state or molecularly dispersed in
microspheres. The Tg of PLGA was increased with the addition of DP. The release profile in
vitro was characterized with slow but continuous release that lasted for about one week
and fitted well with first-order model, which suggested the diffusion governing release mecha-
nism. After single-dose administration of DP microspheres via subcutaneous injection in
rats, the plasma concentration of DP reached peak concentration at 0.50 d, and then de-
clined gradually, but was still detectable at 15 d. A good correlation between in vitro and in
vivo data was obtained. The results suggest the potential use of DP microspheres for treat-
ment of Alzheimer’s disease over long periods.
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Alzheimer’s disease (AD) is a progressive neurodegenerative
disease characterized clinically by cognitive decline andmemory
loss. In 2013, Alzheimer’s Disease International (ADI) re-
ported the worldwide prevalence of dementia to be more than
44 million [1–3].With the progress of AD,AD patients may start
to suffer from memory loss and thinking disorders from the
mild stage of AD.As a consequence, they need to get some help
with their routine daily activities and health care to avoid over-
dosing on medicine or missing doses due to memory loss. Even
worse, some psychological problems may occur to some pa-
tients with severe AD and they might refuse to take medicine.
Furthermore, since the primary patient population of AD is the
elderly, most of them are likely to have several other dis-
eases apart from AD, and they may need to take various
medicines, which make their medication regimen more com-
plicated, seriously compromising their compliance.
Donepezil (DP), the second generation of cholinesterase in-
hibitors, approved by the FDA in 1996, was thought to be able
to improve cognitive function in patients with AD, and showed
less hepatotoxicity and better tolerance compared to its pre-
decessor (tacrine), and it associated with a smaller risk of clinical
trial dropout rate than rivastigmine and galantamine [4]. Cur-
rently, DP is only commercially available in the oral
administration dosage form of tablets and capsules. However,
the difficulty in swallowing that elderly people usually have
and the gastrointestinal side effects of DP may result in the
patients’ poor compliance and even the interruption or failure
of treatment. Therefore, a long-term sustained release dosage
form administrated via non-oral route is highly desirable for
AD patients, with the purpose of improving patient compliance.
As an FDA-approved polymer, poly(d,l-lactic-co-glycolic acid)
(PLGA), has beenwidely used in controlled drug delivery systems
(DDSs) due to its biodegradability and biocompatibility. PLGA-
based DDSs such as microspheres, nanoparticles and implants
could provide long-term sustained release of payload from
several days to months to meet different clinical demands. Cur-
rently, there are already several PLGA-based products
commercially available for the sustained release of encapsu-
lated small molecule drug, proteins or peptides [5].
In a previous study of Zhang et al. [6], DP was encapsu-
lated into the matrix of PLGA microspheres and the release
of DP lasted at least one month.The results clearly showed that
PLGA microspheres are a promising carrier of DP for long-
term sustained release. However, the physicochemical properties
of these microspheres have not been studied intensively, and
the formulation has not been optimized to achieve high enough
drug loading and encapsulation efficiency (EE), which are criti-
cal to improve the delivery efficiency.The lack of in vitro–in vivo
correlation (IVIVC) in the previous study made it impossible
to predict the in vivo performance of formulations by looking
at their in vitro release data and further optimize the formu-
lation rationally. In addition, in order to fulfill various clinical
demands, it is necessary to design other DP products which
can achieve sustained release over a shorter period than one
month.The main advantage of having another DP-loaded PLGA
microspheres showing shorter release period is the better flex-
ibility of dose adjustment.With the short release formulation,
the dose could be easily regulated according to the pharma-
codynamics response of the patient, which is especially
important at the beginning of treatment.
2. Materials and methods
2.1. Materials and animals
PLGA 7505 (lactide/glycolide 75/25,Mw 5000 Da, acid-terminated)
was purchased fromWako Pure Chemical Industries, Ltd (Osaka,
Japan). For the preparation of microspheres, polyvinyl alcohol
(PVA) POVAL®-217SB (88% hydrolyzed, KURARAY Co., Ltd. Osaka,
Japan) were used. Methanol, acetonitrile and tetrahydrofuran
(THF) were of high-performance liquid chromatography (HPLC)
grade and obtained from theYuwang Pharmaceutical Co., Ltd.
(Shandong, China). Donepezil hydrochloride (DP·HCl) was pur-
chased from Jinan Dexinjia Biological Products Co., Ltd.
(Shandong, China). All other chemicals or solvent were of ana-
lytical grade or purer and purchased from commercial suppliers.
Wistar rats (male, 220–260 g) were provided by Shenyang
Pharmaceutical University Experimental Animal Center. The
study was approved by the Education and Research Commit-
tee and the Ethics Committee of Shenyang Pharmaceutical
University (approval SYPU-IACUC-C2015-0428-001). Animals
were maintained and experiments were conducted in accor-
dance with the Institutional Animal Care and Use Committee,
Shenyang Pharmaceutical University, and the 1996 Guide for
the Care and Use of Laboratory Animals (Institute of Labora-
tory Animal Resources on Life Sciences, National Research
Council, National Academy of Sciences, Washington DC). All
efforts were made to minimize animal suffering and to limit
the number of animals used.
2.2. Preparation and identification of donepezil free base
DP·HCl 1 g was dissolved completely in double distilled water
(about 20 ml), in which 4% NaOH was dropwise added under
agitation. After the pH of solution reached about 11, the syn-
thetic was extracted with 20 ml ethyl acetate twice, and then
sufficient amount of anhydrous sodium sulfate was added into
the separated organic phase and placed for 24 h to remove re-
sidual water.With the evaporation of ethyl acetate at 40 °C water
bath, the product was collected.
Differential scanning calorimetry (DSC) was used to study
the thermodynamic properties of the obtained product. Samples
were placed in aluminium pans and heated at a scanning rate
of 10 °C/min from 25 °C to 250 °C under a nitrogen atmosphere.
2.3. Preparation of donepezil loaded PLGA microspheres
DP-loaded PLGA microspheres were prepared by a conven-
tional O/W emulsion-solvent evaporation method [7]. Briefly,
5 mg DP and 20 mg of PLGA were dissolved in 200 µl of
dichloromethane (DCM), then injected into 4 ml aqueous phase
containing certain concentration of PVA as emulsifier and ho-
mogenized with a high speed dispersion homogenizer (FJ200-
S, Shanghai specimen model Factory, China) under 1500 rpm
for 4 min to form an O/W emulsion. The emulsion was
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subsequently transferred to a larger volume of distilled water
or PVA solution to dilute the emulsion and avoid the aggre-
gation of particles. After the emulsion was stirred for 4 h at
room temperature to evaporate the solvent, the microspheres
were collected by centrifugation under 252 g (1500 rpm) for
3 min (800-centrifuge, Jintan Ronghua instrument manufac-
ture Co., Ltd. China), washed three times with redistilled water
and then lyophilized (DRC-1000REC Freeze Dryer,Tokyo Rikakikai
Co., Ltd. Japan), stored at −20 °C.The blank microspheres were
prepared by following the same procedure except for the adding
of DP.
2.4. Particle size and morphology
During solvent evaporation procedure optical microscope (XSP-
2CA, Shanghai CSOIF Co., Ltd. China) was used for particle
observation, and photos were taken by digital camera.The size
distribution was determined with Laser Particle Size Ana-
lyzer (Coulter LS-230, Beckman Coulter Co., Ltd. USA). The
volumeweightedmean diameter (vol-wtmean) of microspheres
is reported as particle size and the span value (SP) was cal-
culated with the following formula: SP = (d90 − d10)/d50, where
d90 is the particle diameter at 90% cumulative size, d10 is the
particle diameter at 10% cumulative size and d50 is the par-
ticle diameter at 50% cumulative size. The size distribution is
considered as narrow for span values <0.45.
The surface morphology of the microspheres was ob-
served by optical microscope or scanning electron microscopy
(SEM) (S-3400, Hitachi, Ltd., Japan). With SEM, freeze-dried
microspheres mounted on aluminum stubs with double-
sided tape and coated with a thin layer of gold. The coated
specimen was then scanned and photographed under the mi-
croscope at an acceleration voltage of 5.0 kV.
2.5. Drug loading and encapsulation efficiency
determination
A drug extraction method was developed for drug loading and
EE determination. About 2 mg microspheres were dissolved in
200 µl acetonitrile and extracted with 4 ml of 0.012 M HCl by
vortex for 4 min). The supernatant was collected by centrifu-
gation for DP content determination. The recovery rate of the
extraction procedure was 97.55 ± 1.02% (n = 6).
The DP loading and EE were calculated using the follow-
ing Eqs. (1) and (2):
Drug loading












Quantification of DP in various assay samples was carried out
using an HPLC system consisting of a Hitachi L2130 HPLC pump
(flow 1 ml/min), a Hitachi L-2420UV detector (UV-detection
271 nm), a Hitachi L-2200 autosampler and an ODS-C18 column
(Dikma, 4.6 mm × 200 mm, 5 µm).
For the analysis of in vitro assay samples, the mobile phase
was 65%methanol and 35% water containing 0.5% glacial acetic
acid and 1% triethylamine. Integration of peak areas was uti-
lized for quantification of sample concentrations and
calculations were performed on the basis of standard curves.
The standard curve was A = 35385C − 5.7560 (R2 = 0.9999, the con-
centration range was 0.08–20.00 µg/ml). A represents the peak
area and C represents the concentration of DP.The lower limit
of quantification was 40 ng/ml and the lower limit of detec-
tion was 20 ng/ml.
For in vivo biologic samples, the mobile phase consisted of
60% methanol and 40% glacial acetic acid solution (0.5%) ad-
justed to pH 6.5 with triethylamine. The standard curve was
Ai/As = 0.8159C + 0.0180 (R2 = 1.0000, and the concentration range
was 0.05–2.00 µg/ml). Ai and As represent the peak area of in-
ternal standard and DP, respectively, and C represents the
concentration of DP.The lower limit of quantification was 50 ng/
ml and the lower limit of detection was 25 ng/ml.
2.7. Differential scanning calorimetry
The thermal analysis of pure DP, PLGA, blank microspheres,
physical mixture of DP and PLGA and DP microspheres was
performed to determine the physical state of the drug incor-
porated inside the microspheres and to investigate the effect
of drug on PLGA glass transition temperature (Tg). DSC was per-
formed using METTLER TOLEDO DSC 1 (METTLER TOLEDO,
Switzerland). 5 mg samples were placed in an aluminum pan
and heated at a constant rate of 10 °C/min, using dry atmo-
sphere of nitrogen as carrier gas, in a temperature range of −40
to 150 °C.The instrument temperature and energy scales were
calibrated using purified indium (99.9%) as the standard ref-
erence material.
2.8. X-ray powder diffraction
DP, pure PLGA, physical mixture of DP and PLGA and
microsphere products were studied by X-ray powder diffrac-
tion (XRD) technique using D/MAX-2500PC (RIGAKU, Japan). θ–2θ
powder diffract meters set for an angle range of 3–50° (2θ). The
step size was 0.01° (2θ) and count times were of 1 s per step.
2.9. In vitro release study
In vitro release studies were conducted with the sample and
separate techniques [8].Approximately 2mg of DPmicrospheres
were suspended in 6.0 ml of phosphate buffer saline (PBS,
pH = 7.4) (sink condition can be maintained) in 10 ml capped
glass centrifuge tube with round bottom and incubated at
37 ± 0.5 °C under 60 rpm horizontal shaking (WHY-2 thermo-
static horizontal oscillator, Dadi auto-instrument, Ltd. Jintan,
China) for 10 d.At each predetermined sampling point, the sus-
pension was centrifuged at 2120 g (3500 rpm) for 5 min (Anke
TDL-40B, Shanghai, China) and the supernatant was sepa-
rated for assay by HPLC method. Fresh medium of the equal
volume was added in the meantime, re-suspended and incu-
bated again. All assays were always performed in triplicate.
2.10. In vitro degradation study
The degradation of PLGAwas characterized bymolecular weight
change. In detail, 3 mg of microspheres were incubated in 1 ml
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release media containing 0.02% NaN3 at 37 ± 0.5 °C, under
60 rpm horizontal shaking with theWHY-2 thermostatic hori-
zontal oscillator and three samples were prepared for each time
point. At different time points (1, 3, 5, 10 d), the three tubes
were taken out and lyophilized, then dissolved with THF and
subjected to gel permeation chromatography (GPC) analysis.
GPC analysis was carried out using a Waters liquid chro-
matograph equipped with pump (Waters 1515 isocratic HPLC
pump) and column oven in combination with a differential re-
fraction detector (Waters 2414 refractive index detector).A series
of Chromatographic columnwere applied: Styragel HT3 Column,
10 µm, 7.8 × 300 mm (THF), Styragel HT4 Column, 10 µm,
7.8 × 300 mm (THF), Styragel HT5 Column, 10 µm, 7.8 × 300 mm
(THF) (Waters, USA). THF was used as the mobile phase with
the flow of 1 ml/min, and the injection volume of assay sample
was 20 µl. The column temperature was set at 30 °C. A uni-
versal calibration method (third-order polynomial fit,
R2 = 0.99996) was applied to determine the molecular weight
of PLGA,which was obtained from polystyrene standards ranged
from 1200 to 125,000 Da in their molecular weight. Data ac-
quisition was performed using Breeze version 3.30 SPA software
(Waters).
2.11. In vivo pharmacokinetic study
In pharmacokinetic study, the rats were randomly divided into
two groups. One group (n = 4) received DP·HCl aqueous solu-
tion administered intravenously (30 mg/kg) while the other
group (n = 4) was given DP microspheres (corresponding to
280 mg DP /kg) by subcutaneous injection at the back of rats
after reconstitution with a viscous aqueous vehicle (0.5% car-
boxymethylcellulose, w/v). At predetermined interval, blood
samples (0.3 ml) were withdrawn via the orbital vein with hepa-
rinized tubes. The sampling time point for DP·HCl aqueous
solution group was 5, 10, 15, 30, 60, 90, 120, 180, 240, 300, 360,
420, 480, 600, and 720 min after i.v. and 0.2, 0.5, 1, 1.5, 2, 2.5, 3,
3.5, 4, 4.5, 5 d and then once a day for DP microspheres group.
And then plasma was separated immediately by centrifuga-
tion and stored at −80 °C until assay.
Plasma samples were processed by following the proce-
dure below: 100 µl of plasma sample was mixed with 10 µl of
NaOH solution (0.5 M).Then 10 µl of Ethylparaben (internal stan-
dard) methanol-water (60:40, v/v) solution (5 µg/ml) was added
to the mixture and vortexed for 1 min. The mixture was ex-
tracted with 1 ml of ethyl acetate by vortex for 5 min. After
centrifugation for 5 min under the force of 17,788 g (16,000 rpm),
the organic layer was taken and dried with nitrogen. The re-
siduals after the removal of solvent were then reconstituted
with 100 µl of mobile phase and the content of DP in it was
determined by using the established HPLC. The recovery rate
of DP extraction from plasma sample was 80.61 ± 2.27%,
85.98 ± 4.42%, 87.55 ± 1.89% (mean ± SD, n = 3) under three con-
centration levels (0.10 µg/ml, 0.20 µg/ml, 1.00 µg/ml), respectively.
2.12. In vitro/in vivo correlation
A two-stagemodeling process was applied to evaluate the IVIVC
for DP loaded microspheres according to a former literature
[9]. First, in vivo absorption data of DP microspheres in rats were
obtained by the deconvolution of the plasma concentration data,
in which the in vivo results of DP solution after injection ad-
ministrated to rats were used as weight function. Then the in
vivo absorption profile obtained is connected to the time course
of the in vitro release profile.
The correlation analysis was performed with the help of the
IVIVC Toolkit of WinNonlin 5.2.1 (Pharsight), and correlation
coefficients were examined for significance (P < 0.05) using Stu-
dent’s t-test.
2.13. Statistical analysis
Data were presented as mean ± standard deviation. Signifi-
cant differences were determined using analysis of variance
(ANOVA). Results were considered significant if P < 0.05. Cal-
culations were performed using SPSS 16.0 software.
3. Results and discussion
3.1. Preparation and identification of donepezil free base
In the market, DP is usually available in the form of DP·HCl,
which is highly soluble in water. However, as far as the en-
capsulation efficiency (EE) of PLGA microspheres is concerned,
the high water solubility of the drug is unfavorable because
the drug will tend to leak into the water phase. Therefore, DP
free base instead of DP·HCl was used in the current study with
the purpose of achieving high EE.
DP free base was prepared simply by alkalization of DP·HCl
with NaOH and then extracted with ethyl acetate. With the
evaporation of solvent, some white crystal product was ob-
tained, and the yield was over 90%. The purity of DP was
determined by HPLC peak area normalization method and
higher than 99%.The DSC curve of synthesized product showed
a characteristic sharp endothermic peak at 87.26 °C which was
consistent with its melting point reported in literature [10],
which clearly means the successful preparation of DP free base
(Fig. 1).
Fig. 1 – DSC curves of donepezil and donepezil
hydrochloride at heating rate of 10 °C/min.
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3.2. Optimizing the formulation of DP microspheres
The classic O/W emulsion solvent evaporation method was
employed to produce the DP loaded PLGA microspheres
since DP was readily co-dissolved in DCM with PLGA and
high encapsulation efficiency could be expected. However,
the phenomenon of severe fragmentation of microspheres
was observed in our preliminary study, and it was found that
the concentration of PVA in outer water phase was the
determinate factor influencing the integrity of microspheres.
In order to obtain smooth and spherical-shaped microspheres,
the formulation was optimized by varying the concentration
of PVA. The detail of the formulations is shown in Table 1. As
shown in Fig. 2a, when 1% PVA was applied (formulation A),
obvious fragmentation of microspheres occurred during DCM
evaporation process, which might be mainly caused by the
poor plasticity of the low molecular weight PLGA we used.
When the primary emulsion was diluted with 0.5% PVA
instead of distilled water as we did with formulation B, there
were more spherical particles appearing in the field of view
under optical microscopy (Fig. 2b), which indicated that
increasing the concentration of PVA has the potential of
improving the morphology of microspheres. Subsequently,
3% PVA was chosen as the stabilizer to form the emulsion
and then the emulsion was further diluted with 2% PVA as
shown in formulation C. As expected, spherical and inte-
grated microspheres were successfully prepared finally (Fig. 2c)
Therefore, formulation C was considered to be the optimal
formulation and in the following experiment, all the
microspheres were prepared with this formulation unless
otherwise stated.
Irregular particles were obtained in other research when the
content of PVA was low [11]. It has been demonstrated that PVA
bound on the microparticle surface in an irreversible manner
[12]. The low concentration of PVA in water phase was not
enough for forming integrated coating on the surface of emul-
sion droplets and therefore had weaker stable effect.
3.3. Characterization of DP microspheres
The optimized PLGAmicrospheres were characterized in terms
of particle size, size distribution, morphology, drug loading and
EE. As shown in Fig. 2d, the particle size distribution of pre-
pared PLGAmicrospheres was narrow andmonodispersed,with
the mean diameter of 29.4 ± 17.1 µm, d10 of 8.95 µm, d50 of
27.64 µm, d90 of 51.28 µm and span value of 0.85. There were
no particles larger than 100 µm. It has been well known that
particle size and its distribution will significantly affect the in
vitro release in microspheres system. For hydrophobic drugs,
the removal of drug out from boundary layer was crucial during
drug release. High ratio of surface area and volume such as a
decrease in the particle size always lead to a higher release.
The particle size obtained was considered to be beneficial for
faster drug release rate.
SEM observation of microspheres revealed a non-porous,
smooth surface structure with no drug crystals on its surface
as shown in Fig. 2e and 2f. The particle size observed by SEM
was consistent with that obtained from microscope and
Beckman laser particle size analyzer. The section of
microspheres showed an internal dense structure with occa-
sional small pore (the white arrow in Fig. 2f).
In order tomeasure the loading and EE of DP inmicrospheres
accurately, a new method for the extraction of DP from PLGA
microspheres was developed. In this method, certain amount
of microspheres was dissolved by acetonitrile prior to the ad-
dition of hydrochloric acid solution. During the process of
extraction by vortex, huge acetonitrile–water interface was
formed, and on the interface an acid–base reaction between
acid and DP happened. The reaction converted the insoluble
DP into its soluble counterpart DP·HCl, which could be easily
partitioned into water phase. HPLC system can be used during
the determination of DP loading based on this drug extrac-
tion method.
The determined drug loading was 15.92 ± 0.31% and the
average EE was 78.79 ± 2.56% for three batches of DP loaded
microspheres, which are significantly higher than that of the
previous report mentioned [6]. Actually, this result was not out
of expectation at all since the DP free base we used in our study
has much lower solubility than DP·HCl that has been used in
previous study. The solubility of encapsulated drug is one of
the critical factors determining the EE when emulsion solvent
evaporation method was applied. Drugs with high water solu-
bility tend to leak into outer water phase during preparation
process, which usually result in low encapsulation efficiency.
The strategies such as increasing the viscosity of polymer so-
lution by increasing the polymer concentration or molecular
weight are commonly used to increase EE [13]. Compared to
the same previous study [6], although the molecular weight of
the PLGA we used was lower, the higher concentration of PLGA
resulted in muchmore viscous oil phase, which also could con-
tribute to the improved EE. In addition, it was reported that
the ionic interaction between basic amino residue of the drug
and uncapped carboxylic acid end-group of the polymers plays
an important role in the encapsulation of drugs [14–17]. This
is the reason why we selected the carboxyl terminal PLGA.
However the information about the end group of the PLGA they
used was missed, therefore it is impossible to discuss its effects
on EE.
Table 1 – Formulations and morphology of DP loaded microspheres.
Formulation A B C
PLGA (mg) 20 20 20
Organic phase 200 µl DCM DCM DCM
Aqueous phase: 4 ml 1% PVA (No. 1) 1% PVA (No. 1) 3% PVA (No. 1)




Appearance compared with formulation A – Better Good and almost no fragment
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DSC is a useful technique to investigate the change in the
physical state of drug in microspheres during preparation
process. DSC thermograms of pure DP, blank microspheres, DP
loadedmicrospheres and physical mixture of DP and PLGAwere
shown in Fig. 3. It was found that both pure DP and physical
mixture of DP and PLGA presented a sharp endothermic peak
at the position corresponding to the melting point of DP
(87.26 °C), but the peak disappeared in the curve of DP loaded
microspheres which indicated that DP was amorphous or mo-
lecularly dispersed in microspheres.
Fig. 2 – Particle size and morphology of DP loaded microspheres (a–c are microscope images for Formulation A–C,
respectively. The magnification time was 10 × 10, one units represent 23 µm; d was particle size distribution of fomulation
C; e and f was SEM image of formulation C under a different view).
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Thermograms obtained from the first heating cycle pro-
vided information on the actual physical and morphological
changes within the particle matrix [18]. So we recorded the glass
transition temperatures (Tg) of PLGA from first cycle, and the
value was 38.5 °C for bulk PLGA, 34.8 °C for blank microspheres
and 43.7 °C for DP loaded microspheres.We can find that the
Tg of PLGAwas decreased about 3.7 °C after blankmicrospheres
were prepared, which could be attributed to the plasticizing
effect of residual water or DCM [5]. It has been reported that
PVA plays an antiplasticizing effect on PLGA due to its hy-
droxyl groups which has the potential to interact with PLGA.
It’s obvious that the antiplasticizing effect of PVA was much
weaker compared with the plasticizing effect induced by re-
sidual water or DCM [18]. On the other hand, it was interesting
to find that the incorporation of DP within PLGA increased the
Tg of PLGA from 34.8 °C to 43.7 °C. This is not common since
in most cases, drug presented in microspheres act as a plas-
ticizer and would reduce Tg of polymer due to the interactions
between drug and polymer. The same phenomenon has been
observed in Gentamycin/poly (dl-lactic acid) blends in which
both gentamycin base and gentamycin sulfate increased Tg of
polymer [19].This strong anti-plasticizing effect of DP on PLGA
must be due to the reduced mobility of PLGA chain with the
involvement of DP. It was assumed that DP could act as filler
to occupy the vacancy of PLGA chain, which may decrease the
free volume of PLGA. However, we believed this effect was
limited, and there must be other more strong effect existing
in light of the great increase of Tg (about 8.9 °C).We found that
there are four H bond acceptors in DP molecular which may
interact with carboxyl terminal of PLGA chain ends and form
stable clusters and thus increase Tg.The baseline drift was ob-
served after the glass transition peak which was attributed to
the structural relaxation of PLGA [18].
Further investigation of the crystallization properties of DP
in the drug-loaded microspheres was performed using XRD
technique. Fig. 4 shows the XRD patterns of DP, blank
microspheres, DP loaded PLGA microspheres and physical
mixture of DP and PLGA.The analysis by XRD of the DP powder
demonstrated the presence of many diffraction bands which
were characteristic of a crystallinematerial.The absence of char-
acteristic peaks in XRD pattern of DP loaded microspheres
confirmed the amorphous state of DP in the matrix of PLGA.
3.4. DP-loaded microspheres providing long-term
sustained release both in-vitro and in-vivo
As we mentioned above, the purpose of the current study was
to develop a PLGA microspheres-based formulation for DP in-
jection which was expected to provide sustained release for
about one week. Therefore, the PLGA with the glycolic acid to
lactic acid ratio of 75:25 and lowmolecular weight about 5000 Da
was adopted to encapsulate the DP.The release behavior of pre-
pared DP-loaded PLGA microspheres was investigated both in
vitro and in vivo. From the obtained in-vitro release profile (Fig. 5),
it can be seen that under in-vitro conditions, DP was released
slowly and continuously with no obvious initial burst release,
Fig. 3 – DSC patterns of DP, Blank microspheres, DP loaded
microspheres and physical mixture of DP and PLGA.
Fig. 4 – Powder XRD patterns of DP, PLGA, DP loaded
microspheres and physical mixture of DP and PLGA.
Fig. 5 – In vitro release profile of DP loaded PLGA
microspheres.
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and about 88.44% of total DP was cumulatively released over
10 d. Obviously, this release pattern was different from the
typical triphasic release profile which presents an initial burst
release phase followed by the lag phase and the third con-
tinuous release phase. Here, the phase of initial burst release
and lag phase were missed.The in-vitro release data were fitted
to various mathematical models including the first-order and
Higuchi equation in an attempt to figure out the mechanism
that governed the release kinetics of DP-loaded PLGA
microspheres. According to the data of mathematical model-
ing listed in Table 2, it can be seen that the regression (R) was
more than 0.99 for the models except for Higuchi equation. It
seemed that all these three models (First-order, Korsmeyer–
Peppas andWeibull model) were appropriate to model the drug
release behavior. In the Korsmeyer–Peppas model, k is a system
specifics constant and n is the diffusion exponent [20] that cor-
responds to the transport mechanism. In this case, n was
smaller than 0.43 (n = 0.27), it can be suggested that the dif-
fusion controlled drug release [21]. The fitting for the First-
order model with first-order release constant of 0.573 which
also suggested the diffusion of DP driven by the concentra-
tion gradient was the main release mechanism. In theWeibull
model, a link between the values of b and the diffusional
mechanisms of the release have been found [22], when the value
of b was 0.619, which was lower than the 0.75 release that
follows Fickian diffusion. The conclusion of diffusion con-
trolled release was also supported by the data about the change
of molecular weight of PLGA during the in vitro release process
(shown in Table 3). It was evident that the molecular weight
of PLGA was almost constant over the 10 d of release; there-
fore the release was polymer degradation independent.
Drug release frommicrospheres was fast, and this was con-
tributed to both aspects from PLGA and drug. First, DP dispersed
in this PLGA microspheres system as an amorphous or mo-
lecular from. In both cases, the situation was that the free DP
molecular provides enough diving force for diffusion. On the
other hand, it has always been known that for diffusion-
controlled release the dissolved drug needs to pass through
the PLGA matrix or water-filled pores [23]. It has been ob-
served that there were no significant pores both on the surface
and interior of microspheres system. PLGA acts as a diffu-
sion barrier, and its properties will significantly affect drug
release. Since the Mw of PLGAwe selected was small, the overall
mobility of their chains was high and therefore allows DP to
pass through the polymer matrix faster [24]. Furthermore, car-
boxyl end-group further increases the hydrophilicity of PLGA
and thus water can penetrate more quickly and hydrate the
polymer.
The mean plasma concentration-time profiles of DP in rats
after i.v. administration of pure DP·HCl solution and i.m. ad-
ministration of DP loaded PLGA microspheres are shown in
Fig. 6 and Fig. 7.The main calculated pharmacokinetic param-
eters are listed in Table 4.
Table 2 – Results of DP release profile fitting for different
mathematical models.
Model Equation Correlation coefficient
Higuchi F k t TH lag= ⋅ −( )1 2 0.9514
First-order M
M
et k t Tlag
∞
− ⋅ −( )
= −1 1
0.9918
Korsmeyer–Peppas F k t TKP lag
n
= ⋅ −( ) 0.9955
Weibull M
M
et a t Tlag
b
∞
− ⋅ −( )
= −1
0.9991
Table 3 – Mw change of PLGA in DP microspheres after
preparation and incubation in release media.
Time (d) Molecular weight of PLGA (Da)
Original PLGA 6249 ± 89
0 6240 ± 105
1 5450 ± 138
3 5381 ± 61
5 5357 ± 42
10 5177 ± 112
Fig. 6 – Plasma concentration-time profiles of DP after
intravenous (i.v.) injection of DP 3 mg/kg (dissolved in
saline (1 mg/ml)) via the tail vein (n = 4) in rats.
Fig. 7 – Plasma concentration-time profiles of DP after the
application of DP loaded PLGA microspheres (280 mg DP/
kg) in rats (n = 4).
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After single-dose administration of DP loaded microspheres
via subcutaneous injection route, the plasma concentration of
DP reached peak concentration (Cmax) 563.45 ± 84.50 ng/ml at
the time point of 0.50 d, and then the concentration declined
gradually, but was still was detectable at 15 d after adminis-
tration. Compared to DP·HCl solution administered via i.v.
injection, the MRT value of DP-MS was prolonged to 8.72 ± 1.07
d, which was 80-fold longer than that of pure DP·HCl solu-
tion. These results further confirmed the obvious sustainable
release properties of the microspheres.
IVIVC is a predictive model which can be used to describe
the relationship between in vitro behavior of a dosage form and
relevant in vivo response. As presented in Fig. 8, the mean
deconvoluted absorption profile in vivo of different rats was in
agreement with the observed release profile in vitro, and the
correlation coefficient was 0.9768.
A level A correlation which was the most informative and
recommended by the FDA was obtained in this study. Based
on the good in vivo/in vitro relationship, the in vitro drug release
testing can be used to predict the in vivo performance of the
corresponding formulation, which means that we could use
the in vitro drug release testing to optimize the formulation at
the stage of formulation development, and to control the quality
of the product during the produce process. Furthermore, on
the basis of the level A correlation between in vitro release and
in vivo profiles, the in vitro release test cannot only serve as a
tool to assure batch-to-batch uniformity for a product but also
the evaluation of bioequivalence.
4. Conclusion
DPmicrospheres with integrated sphere morphology were pre-
pared successfully with 3% PVA as emulsifier. Higher
encapsulation efficiency of 78.79 ± 2.56% was obtained. Se-
lected PLGA can control DP release that last for one week in
vitro. The release data fit well with first order, Korsmeyer–
Peppas and Weibull model, suggesting diffusion-controlled
release of this DP microspheres system. Sustained and steady
plasma DP concentration was obtained after subcutaneous in-
jection into rats, indicating the slow absorption of DP in vivo.
And good in vitro–in vivo correlation was obtained.These results
suggested the potential use of DP loaded PLGA microspheres
for treatment of AD over long periods.
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